MYH9 and neoplasm: It has been revealed for the first time that EBV-miR-BART22 directly targets MAP2K4 and stimulates Myh9 expression, thereby inducing the ubiquitin degradation of GSK3β protein and consequently promoting tumor stemness, metastasis, and cisplatin chemoresistance via the activation of β-catenin-induced stemness and EMT signals (84).